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(Busilvex) (3.2mg/kg/day for 3 days), Etoposide (400mg/m2/
day for 2 days) and Melphalan (140mg/m2) (BEM). We
retrospectively analysed the outcome of patients (pts) who
underwent AHCT following conditioning with the standard
BEAM and BEM regimen. The pts were stratiﬁed by age, pre-
transplantation disease phase and previous lines of treat-
ment. In total, 50 pts conditioned with BEM (group A) and 93
pts with BEAM (group B) were included. Group B pts were
selected among 184 pts who underwent AHCT with BEAM
regimen during the last decade. Stratiﬁcation by disease risk
was followed by a 1:2 selection. Fifty percent of the pts were
younger than 34 in both study groups with a range of 11-68
years old. The pts of group B were more likely to suffer from
HL (63) than NHL (30); whereas disease diagnosis for group A
was HL in 28 and NHL in 22 pts. Disease was chemoresistant
to salvage treatment in 46% of group A pts versus (vs) 23% of
group B pts. There were no other signiﬁcant differences
concerning the patients’ characteristics such as age above
median, pre-transplantation lines of treatment (1-2: 40%, 3-
4: 46%, 5: 14%), disease status (complete remission: 27%,
primary refractory: 52%, relapse: 21%), advanced stage
disease (52%). Complete remission post-AHCT was obtained
in 50% of group A and 56% of group B pts. Progression free
survival (PFS) at 2 years and overall survival (OS) were
similar among the two study group populations (66% vs 63%
and 80% vs 78% respectively). Given the fact that there were
more pts with chemoresistant disease in group A, a second
matched pair analysis was conducted upon stratiﬁcation by
disease chemosensitivity to salvage treatment instead of age
as a risk factor. Efﬁcacy was again similar for both condi-
tioning regimens. In multivariate analysis favorable factors in
terms of PFS were HL, chemosensitivity to salvage treatment
and stage <IIB whereas in terms of OS non-bulky disease,
HL and stage <IIB. Treatment related mortality (TRM) was
3.2% (3/93 pts) in group B and no TRM in group A. Detailed
toxicity associated with the two study regimens is further
analyzed. There are currently no randomized studies clari-
fying the optimal conditioning among multiple regimens in
terms of efﬁcacy and toxicity. In this study the two condi-
tioning regimens, BEAM and BEM, were found to be equiv-
alent. Additionally, the efﬁcacy of the newly designed BEM
regimen in chemoresistant and advanced stage disease is
encouraging.253
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Allogeneic stem cell transplantation (alloSCT) is a poten-
tially curative therapy for patients (pts) with Hodgkin
lymphoma (HL) relapsing after autologous SCT (autoSCT).
Myeloablative conditioning is associated with high non-
relapse mortality (NRM) in this setting and reduced-inten-
sity conditioning is often the preferred option. Historically,
we have used the combination of ﬂudarabine and intrave-
nous busulfan ormelphalan (FB/FM). Over the last 2 years we
used the combination of ﬂudarabine and treosulfan (FT).
Treosulfan is a pro-drug of a bi-functional alkylating agent
with intensive myelosuppressive as well as immunosup-
pressive properties and a relatively favorable toxicity proﬁle.It was predominantly explored in pts with myeloid malig-
nancies and there is only limited data on the expected
outcomes of this regimen in pts with lymphoidmalignancies.
We analyzed the outcomes of 27 pts with HL, given alloSCT,
after failure of a previous autoSCT. The median age was 30
years (range, 20-62), 18 male, 9 female. The donor was an
HLA matched sibling (n¼12), matched unrelated (n¼14) and
umbilical cord blood (n¼1). This was a relatively high-risk
patient groupwith 18 pts having chemo-refractory disease at
SCT and only 9 responded to the last course of therapy.
Nineteen pts were given FB/FM conditioning and the most
recent 8 pts were given FT with a total treosulfan of 30-32 g/
m2. The median follow up of surviving pts is 12 months
(range, 4-85 months). Eight pts are currently alive and
progression-free, 8 pts had NRM and 11 relapsed. All relapses
occurred within the ﬁrst year after SCT. The estimated 2-year
cumulative incidence of NRM and relapsewas 30% (95%CI 17-
53%) and 45% (95%CI 29-70%), respectively. The estimated 2-
year overall survival (OS) rate is 34% (95% CI 14-55%) and the
2-year progression-free survival (PFS) is 25% (95% CI 7-43%).
The 2-year PFS for pts with chemo-sensitive and chemo-
refractory disease was 53% (95%CI, 19-87) and 9% (95%CI, 0-
25), respectively (P ¼ .01). Pts given FB/FM conditioning had
a 2-year PFS of 16% (95%CI, 0-32) compared with pts condi-
tioned with FT who had a PFS of 63% (95%CI, 29-96, P ¼ .18).
In multivariant analysis, chemo-refractory disease was
associated with inferior PFS, HR 4.2 (1.3-13.5), P ¼ .02. There
was a trend for better PFS after FT conditioning, after
adjusting for other variables, HR 0.3 (0.1-1.2), P ¼ .08. Age,
gender and donor type were not signiﬁcant predicting
factors. In conclusion, alloSCT can salvage a subset of pts with
HL relapsing after autoSCT, but has a limited role in pts with
chemo-refractory disease at SCT. Treosulfan-based condi-
tioning is promising in this entity, andmerits further study in
larger comparative studies.254
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Multiple myeloma (MM) is an abnormal proliferation of
plasma cells in the bone marrow. High dose chemotherapy
with autologous stem cell transplantation (ASCT) is an
effective treatment for MM. Induction therapies include
immunomodulatory drugs, proteasome inhibitor, steroids
and DNA alkylating agents in single or tandem ASCT. Despite
the success of ASCT, post-ASCT progression is still a major
problem. Based on our previous work, we hypothesized that
combination of nucleoside analogs + DNA alkylators could
provide synergistic cytotoxicity and may be used as safe and
efﬁcacious conditioning therapy in an ASCT-program. We
exposed human MM cell lines to various combinations of
clofarabine (Clo) and gemcitabine (Gem) with or without
busulfan (Bu) and melphalan (Mel). At less than drug IC10
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[Bu+Mel] combinations did not show synergistic cytotoxicity.
However, a combination of [0.25 mM Clo + 3.5 nM Gem]
resulted in about 60% inhibition of proliferation of p53-wild
type NCI H929 andMM.1R cells; combination indexes¼ 0.1e
0.6 suggested strong synergism. Two p53-mutated MM cell
lines, RPMI 8226 and U266B1, were more resistant to these
drugs. For example, exposure to [0.4 mM Clo+30 nM Gem]
inhibited proliferation of RPMI 8226 only by 25%. To deter-
mine if the cytotoxicity of [Clo+Gem] is mediated by p53,
H929 and MM.1R cells were pre-exposed to a p53-inhibitor,
piﬁthrin a. More than 50% of the [Clo+Gem]-mediated
cytotoxicity was reversed. The level of p53-regulated pro-
apoptotic PUMA and p21 proteins increased with [Clo+Gem]
but the effects were reversed in the presence of piﬁthrin a.
ATM kinasewas activated, further supporting involvement of
the ATM-p53 pathway in activation of DNA-damage
response. Phosphorylation of deoxycytidine kinase (DCK)
increased, and proteins involved in DNA-repair and rRNA
productionwere down-regulated. The activation of apoptosis
is suggested by the cleavage of PARP1 and caspases 3 and 8.
Further, mitochondrial membrane potential (MMP)
decreased in cells exposed to [Clo+Gem] consistent with
increased levels of proapoptotic factors cytochrome c, AIF
and SMAC/DIABLO in the cytosol, suggesting mitochondrial
leaks. These results show that the mechanism of synergistic
cytotoxicity of [Clo+Gem] in p53-positive MM cells involves
activated DCK, DNA-damage response, decreased MMP,
inhibited DNA repair, and nucleolar stress through decreased
rRNA. We are determining the effects of [Clo+Gem] in
primary cell samples from MM patients; the data will be
presented and discussed. Our investigation provides a basis
for introducing nucleoside analog combination(s) in both
cytoreductive induction therapy and pre-ASCT therapy in
MM, and in individualizing therapy based on p53 status to
avoid subjecting patients to ineffective therapy.255
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Background: Standard therapy for multiple myeloma (MM)
includes initial autologous hematopoietic cell trans-
plantation (autoHCT1) but this is not curative and most
patients will relapse. Data on salvage autoHCT2 or allogeneic
HCT (alloHCT2) are limited and the optimal salvage strategy
is unknown.
Methods: This is a retrospective study of MM patients >18
years of age who relapsed after autoHCT1 and underwent
salvage autoHCT2 or alloHCT2 between 1995-2011 at our
institution. Tandem auto-autoHCT or auto-alloHCT were
excluded.
Results: Characteristics of autoHCT2 (N¼27) and alloHCT2
(N¼19) patients were not signiﬁcantly different except the
alloHCT2 median age was signiﬁcantly (P ¼ .002) lower (54
years) than for autoHCT2 (62 years) and more alloHCT2
patients had KPS  70% (P ¼ .031). Complete and very good
partial remission (CR/VGPR) improved from 7% to 56% after
autoHCT2 and from 26% to 37% after alloHCT2. Of 15 patients
with progressive disease (PD) at the time of autoHCT2, 5achieved CR/VGPR and 7 PR. Nonrelapse mortality (NRM) at
3 years was 3.7% for autoHCT2 and 5.3% for alloHCT2 (P ¼
.901). Median progression free survival (PFS) and overall
survival (OS) for autoHCT2 (19 months, 23 months) and
alloHCT2 (6 months, 19 months) were not signiﬁcantly
different. For those entering salvage autoHCT2 in PD, PFS at
3-years was 41.7% (15.2-68.1%) and OS at 3-years was 45%
(16.1-73.9%). On multivariate analysis, time from autoHCT1
to relapse <1year vs. 1year (HR 24.81 [95% CI 2.4-249.9])
and no maintenance therapy vs. given after autoHCT2 (HR
12.19 [95% CI 2.5-249.9] impacted OS after autoHCT2.
However, only time from autoHCT1 to relapse<1 year versus
1 year (HR 18.55 [95% CI 2.28-150.57]) impacted PFS after
autoHCT2. For alloHCT2, no factors impacted NRM, PFS or OS.
For thosewith relapse from autoHCT1<1 year versus1 year
undergoing autoHCT2, median OS was 15 months (1-53) vs.
not yet reached at 143months andmedian PFS was 5months
(1-49) vs. not yet reached at 88 months. Major causes of
death for alloHCT2 were PD (n¼ 5), GVHD (n¼3), while for
autoHCT2, PD (n¼10), infection (n¼3).
Conclusions: Salvage autoHCT2 and alloHCT2 are both
feasible for patients with post autoHCT1MM relapse. Relpase
 1 year from autoHCT1 predicts for better PFS and OS in the
autoHCT2 group. Those with progressive disease can also be
salvaged by autoHCT2. Maintenance therapy after autoHCT2
is beneﬁcial and should routinely be used.256
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Background: High dose chemotherapy followed by autolo-
gous stem cell transplantation (ASCT) is effective therapy for
patients with POEMS syndrome. However, treatment before
ASCT has not been standardized. In addition, patients are at
high risk for an engraftment syndrome (ES) after ASCT, which
is associated with morbidity. Lenalidomide has recently
emerged as therapeutic options in patients with POEMS
syndrome. The purpose of the present study is to evaluate
the role of lenalidomide before ASCT.
Patients: Between December 2005 and May 2011, 7 patients
(pts) with POEMS syndrome underwent ASCT at our insti-
tution (median age at ASCT: 54 years, range: 36-66).
Peripheral blood stem cell (PBSC) was collected using
cyclophosphamide (CY) and granulocyte colony-stimulating
factor (G-CSF). PBSCwas used in 6 pts, whereas bonemarrow
and PBSC were used in a patient. Patients were conditioned
using melphalan (L-PAM; 200mg/sqm: n¼5, 140mg/sqm:
n¼1, 100 mg/sqm: n¼1).
Results: Of 7 pts, 5 have achieved neurologic improvement
after ASCT and are alive with a median follow-up of 44
months (range, 20-81 months), whereas 2 were not evalu-
ated for response because of early death. Interestingly, 2 pts
who had received prior therapy, lenalidomide (Case6: 15-
20mg per day for 53days, Case7: 15mg per day for 15days),
have been alive without ES after ASCT. However, of 5 pts who
had not received lenalidomide, 4 pts had ES after ASCT and
consequently 2 pts died (5 and 7 months).
